San Diego, CA -- (ReleaseWire) -- 07/09/2013 -- Kalos Therapeutics is in a massive growth stage in terms of advancing their cancer "Super Drug" as well as substantially adding top tier board members to ensure continued growth and global exposure. Kalos board member and Time Magazine cover story cancer dream team leader, Dr. Daniel Von Hoff, is an example of the elite nature of the Kalos Therapeutics board.

"Kalos has been blessed with having the world's greatest minds in oncology, drug development and business come together to form our own dream team of recognized global leaders", says Kalos CEO George Colberg. "We are very pleased to announce the addition of another global leader to our dream team - Mr. Derek Vest, CEO & Founder of Gentech Pharmaceutical. Mr. Vest brings great pharmaceutical innovating thinking, passion and excitement to our team as well as providing Kalos with incredible access to Gentech's world-wide team of IT experts."

"Kalos Therapeutics is the only bio-tech/pharmaceutical company in the world that I know of that has the ability to change the world of cancer treatment. Their (Kalos) drug is so elegant and superior in design and delivery compared to any other drug. The ability to provide a drug with next to no side-effects is a dream come true. To have that drug be able to successfully treat nine different types of cancer is a miracle!", says Derek Vest.

About Kalos Therapeutics
Kalos Therapeutics is a biopharmaceutical company that develops and commercializes proprietary product candidates primarily for the treatment of cancer and age related diseases. The ANP family of peptides represents a portfolio from which many therapeutics can be developed addressing multiple indications within cancer, age related diseases and non-malignant hyper proliferative disorders.

Kalos is currently one of the most likely drug companies to develop the holy grail of cancer drugs - or the "Super Drug".

The "Super Drug" in the cancer world refers to a drug that may be used to treat multiple types of cancer and their various strains while avoiding the additional trauma often caused by chemotherapy, radiation and many of the current cancer drugs.

"Kalos has successfully leveraged the natural antiproliferative activity of the Atrial Natriuretic Peptide (ANP) family of peptides in our patented Kalos Motif (s) demonstrating never before seen anti-cancer growth properties" says CEO, George Colberg.

Kalos' drug shows remarkably broad anti-cancer activity, including inhibition of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.

More information can be found on Kalos' web site at http://www.kalostherapeutics.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Cancer "Super Drug" developer Kalos Therapeutics' very own Stand Up To Cancer dream team leader and Chairman of the Kalos SAB, Dr. Daniel Von Hoff, was at the center of the most recent Time Magazine cover story on Cancer and the potential heroes that will be changing our world and the way we think about cancer therapy and treatments.

San Diego, CA -- (ReleaseWire) -- 04/25/2013 -- The Time Magazine cover simply states: "How to Cure Cancer". The story goes into details on why cancer is so difficult to treat and why current therapies and drugs seem to be missing the target. The ability for cancer to mutate and use multiple pathways and receptors to grow is simply staggering. In order to help the process, multiple well-known organizations such as the one embraced by Hollywood and professional sports – Stand Up To Cancer (SU2C) – have been raising huge sums to bring on the best of the best to find a cure for cancer. According to the Time article, "SU2C raises money through foundations and corporate, organizational and private donors and then grants it to teams in the form of unusually large sums (up to $18 million, vs. about $500,000 for a typical grant from the National Institutes of Health, or NIH) to produce results in an aggressively short time, initially three years. All the chosen projects are monitored by the American Association for Cancer Research. An SU2C scientific committee, headed by top-heavy hitters, reviews each team semiannually, a checkup that can make top scientists feel like grad students". (Saporito, 2013, p.32)

"When you have to answer to Nobel laureates and others, it's a very tough review team," says Dr. Daniel Von Hoff, Chief SAB at Kalos Therapeutics, Scientific Officer at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and physician in chief at the Translational Genomics Research Institute. (Saporito, 2013, p.32)

"We are pleased to see our Chief SAB recognized yet again by such an authoritative journal.", said CEO George Colberg. Kalos Therapeutics has been getting plenty of press as of late with the announcement of global patent filing for their new line of cancer drug therapies developed from naturally occurring peptides produced in the body.

Kalos has been able to leverage the natural activities of the ANP family of peptides, which control hyperproliferative cell growth and hemodynamics creating breakthrough therapies for treatment of virulent cancers like pancreatic and ovarian. The "Super Drug" line has been shown effective in nine various forms of cancer and preliminary studies suggest it works without the myriad of side effects that plague every other cancer drug/therapy currently in existence.

Kalos Therapeutics is well-regarded in the pharmaceutical world and biotech world as recruiting the best of the best to develop their patented drugs and unique delivery systems. Having world-class team members such as Dr. Daniel Von Hoff and the Pfizer's former senior research scientist Dr. Michael Kozlowski have allowed for massive advancement in cancer drug development.

About Kalos Therapeutics
Kalos Therapeutics is a biopharmaceutical company that develops and commercializes proprietary product candidates primarily for the treatment of cancer and age related diseases. The ANP family of peptides represents a portfolio from which many therapeutics can be developed addressing multiple indications within cancer, age related diseases and non-malignant hyperproliferative disorders.

References:
Saporito, B. (2013, April). "The Conspiracy to End Cancer". TIME, 30-38.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kalos Therapeutics, Inc. announced that George Colberg, CEO of Kalos Therapeutics, Inc. will be presenting at the 2013 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place April 21-25th at the McCormick Convention and Exhibition Center in Chicago, IL.

San Diego, CA -- (ReleaseWire) -- 04/17/2013 -- George Colberg, CEO of Kalos Therapeutics, Inc. says, "BIO is the biggest and most prestigious event in our industry. It is an honor and pleasure to present at this event. We look forward to sharing the massive progress that Kalos has made this year."

The Bio Tech world has been all ears when it comes to Kalos Therapeutics and its revolutionary new line of cancer drug therapies developed from naturally occurring peptides produced in the body. Kalos has been able to leverage the natural activities of the ANP family of peptides, which control hyperproliferative cell growth and hemodynamics creating breakthrough therapies for treatment of virulent cancers like pancreatic and ovarian. The "Super Drug" line has been shown effective in nine various forms of cancer and preliminary studies suggest it works without the myriad of side effects that plague every other cancer drug/therapy currently in existence.

The BIO organizers are also very interested in the work done by the Kalos dream team including Dr. Daniel Von Hoff (Dream Team leader for Stand Up To Cancer), Dr. Michael Kozlowski (Former lead drug developer for Pfizer), Dr. James Merritt (IDEC, Viagene & Upjohn), & Dr. Marc Garnick (Harvard Medical School Professor & CMO Praecis Pharmaceuticals) to name a few.

About Kalos Therapeutics
Kalos is leveraging the key natural functions of ANP peptides by creating new targeted therapeutics which are cytostatic and not chemotoxic. The company has demonstrated in previous clinical activities that these targeted peptide therapies control cellular proliferation and provide an advantage over traditional chemotoxic drugs by adding hemodynamic controls that will increase naturiesis and diuresis helping to mitigate edema, and ascites in these abdominal cancers. In nature these peptides prevent cardiac remodeling in response to hemodynamic stress by inhibiting cardiac cell proliferation. They also regulate pulmonary hypertension, fat metabolism, and long bone growth. This antiproliferative activities demonstrated broadly across cancer and ophthalmic models makes Kalos a new and dynamic approach to these unmet medical needs.

About The Bio International Convention
The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities.

More information can be found on Kalos' web site at http://www.kalostherapeutics.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (ReleaseWire) -- 03/28/2013 -- Kalos Therapeutics released its live version of Facebook this past week and quickly became one of the fastest growing social media sites for a cancer biotech company.

George Colberg, CEO of Kalos Therapeutics, wanted a way to communicate daily with individuals and families that have been touched by the very forms of cancer that he is dedicated to fighting. "We get emails daily from people that have just been diagnosed with cancer or their family members asking us to help them find the latest information on treatment and clinical trials that might be relevant for them. They are desperate for answers and information on cancer in general as well as updates on our new "Growth Blocking Super Drug" and social media is the answer" says Mr. Colberg.

Kalos Therapeutics is well regarded in the pharmaceutical / biotech world as recruiting the best of the best to develop their patented drugs and unique delivery systems. Having world class team members such as Stand Up To Cancer dream team leader Dr. Daniel Von Hoff and Pfizer's former senior research scientist Dr. Michael Kozlowski have allowed for massive advancement in cancer drug development. As part of Kalos' strategy to "think outside the box" they enlisted the services of another pharmaceutical company to develop an advanced integration between the Kalos website, Facebook and YouTube channel. "Kalos is blessed to have the resources and connections with other large pharmaceutical companies including Gentech Pharmaceutical whom we engaged to design and develop our online presence" said Colberg.

https://www.facebook.com/KalosTherapeutics

Kalos is currently one of the most likely drug companies to develop the holy grail of cancer drugs – or the "Super Drug".

The "Super Drug" in the cancer world refers to a drug that may be used to treat multiple types of cancer and their various strains while avoiding the additional trauma often caused by chemotherapy, radiation and many of the current cancer drugs.

"Kalos has successfully leveraged the natural antiproliferative activity of the Atrial Natriuretic Peptide (ANP) family of peptides in our patented Kalos Motif (s) demonstrating never before seen anti-cancer growth properties" says CEO, George Colberg.

Kalos' drug shows remarkably broad anti-cancer activity, including inhibition of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.

About Kalos Therapeutics
Kalos Therapeutics is a biopharmaceutical company that develops and commercializes proprietary product candidates primarily for the treatment of cancer and age related diseases. The ANP family of peptides represents a portfolio from which many therapeutics can be developed addressing multiple indications within cancer, age related diseases and non-malignant hyper proliferative disorders.

More information can be found on Kalos' web site at http://www.kalostherapeutics.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm